On September 10, 2026 Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, reported its financial results for its first quarter of fiscal 2027, ended July 31, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
First Quarter and Recent Highlights:
•Revenue of $15.2 million, an increase of 8.8% year over year
•Oncology services margin of 51%, compared with 43% in the prior-year period
•Adjusted EBITDA of $671,000, compared with $59,000 in the prior-year period
•Continued investment in the Company’s commercial organization, data platform and strategic growth initiatives
Robert Brainin, CEO of Champions, commented, "We delivered strong performance in the first quarter of fiscal 2027, with improved study execution and conversion in our core research services business driving higher revenue and materially better margins. We are also seeing increased commercial activity around our data offerings as we work to broaden that business across a larger customer base."
"At the same time, we continued to invest in our commercial organization, radiopharmaceutical capabilities, data platform and target discovery initiatives. Our focus remains on building sustainable growth across the business while continuing to improve profitability."
David Miller, CFO of Champions, added, "Revenue increased 8.8% in the first quarter, while oncology services margin improved to 51% from 43% in the prior-year period. Adjusted EBITDA increased to $671,000 from $59,000 in the prior-year quarter, demonstrating the operating leverage in the business as revenue grows.
"We are continuing to build on the foundation established last year, with a focus on driving revenue growth, maintaining expense discipline and converting that growth into improved profitability."
First Fiscal Quarter Financial Results
Total oncology revenue increased 8.8% to $15.2 million from $14.0 million in the prior-year period. Growth was driven primarily by higher core research services revenue, reflecting improved conversion of contracted work into revenue, together with increased data license revenue.
Total costs and operating expenses for the first quarter of fiscal 2027 were $15.6 million compared to $14.5 million in the prior-year period, an increase of $1.1 million or 7.7%.
For the first quarter of fiscal 2027, Champions reported a net loss of $426,000, compared with a net loss of $466,000 in the prior-year period. Adjusted EBITDA, which is defined as net loss excluding stock-based compensation, depreciation and amortization expenses, other income or expense, taxes and a loss on the disposal of lab equipment, increased to $671,000 from $59,000, reflecting higher revenue and improved oncology services margin while the Company continued to invest in its expanded commercial organization and growth initiatives. The current-quarter net loss included $766,000 of stock-based compensation and $314,000 of depreciation and amortization expense.
Cost of oncology revenue was $7.5 million, for the three months ended July 31, 2026, a decrease of $461,000, or 5.8%, compared to $8.0 million in the prior-year period. Oncology services margin improved to 51% from 43% in the prior-year period, reflecting higher revenue and lower third-party radiolabeling costs. Oncology services margin and profit are defined below in our Non-GAAP financial information discussion.
Research and development expense for the three months ended July 31, 2026 was $2.3 million, an increase of $262,000 or 12.6%, compared to $2.1 million for the three months ended July 31, 2025. The increase was primarily attributable to higher share-based compensation expense related to Corellia, our wholly owned subsidiary focused on target discovery. Sales and marketing expense for the quarter was $3.1 million, an increase of $1.2 million, or 66.6%, compared to $1.9 million in the prior year period. The increase reflected the Company’s previously discussed investment in expanding its commercial organization to support growth in both research services and data licensing. General and administrative expense for the three months ended July 31, 2026 was $2.7 million, an increase of $103,000, or 4.0%, compared to $2.6 million for the three months ended July 31, 2025.
Net cash used in operating activities was approximately $492,000 for the quarter, driven primarily by normal working capital movements, including a decrease in accounts payable and an increase in accounts receivable. The Company ended the quarter with approximately $4.4 million of cash and no debt.
Conference Call Information:
The Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its first quarter financial results. To participate in the call, please call 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 938837, or provide the verbal reference "Champions Oncology".
(Press release, Champions Oncology, SEP 10, 2026, View Source [SID1234670717])